Request Demo

Last update 08 May 2025

Atypical Squamous Cells of the Cervix

Last update 08 May 2025

Basic Info

Synonyms

ASC Atypical Squamous Cells, ASC H Atypical Squamous Cells, Cannot Rule Out High Grade Squamous Intra epithelial Lesion, ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-epithelial Lesion

+ [25]

Introduction

Morphological abnormalities of the cervical EPITHELIUM, usually revealed in PAP SMEAR, which do not meet the criteria for squamous CERVICAL INTRAEPITHELIAL NEOPLASIA or SQUAMOUS CELL CARCINOMAS of the CERVIX . It may be a sign of infection with certain types of human papillomavirus (HPV).or sign of a benign (not cancer) growth, such as a cyst or polyp or, in menopausal women, of low hormone levels. More testing, such as HPV test, may be needed.

Drugs associated with Atypical Squamous Cells of the Cervix

pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN(Papivax Biotech, Inc.)

Target-

Mechanism

Immunostimulants

Active Org.

Papivax Biotech, Inc.

Originator Org.

Papivax Biotech, Inc.

Active Indication

HPV-related carcinoma [+2]

Inactive Indication

Atypical Squamous Cells of the Cervix

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

pNGVL4aCRTE6E7L2

Target-

Mechanism

Immunostimulants

Active Org.

The Johns Hopkins University [+2]

Originator Org.

The University of Alabama at Birmingham

Active Indication

Atypical Squamous Cells of the Cervix [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

FluBHPVE6E7

Target

HPV E6 x HPV E7

Mechanism

E7 inhibitors [+1]

Active Org.

BlueSky Immunotherapies GmbH

Originator Org.-

Active Indication

HPV positive oropharyngeal squamous cell carcinoma [+5]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Atypical Squamous Cells of the Cervix

NCT05829629

/ RecruitingPhase 1

Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women with NILM, ASC-US, LSIL or Low-grade CIN

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Start Date12 Sep 2023

Sponsor / Collaborator

BlueSky Immunotherapies GmbH

NCT03913117

/ RecruitingPhase 1IIT

Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4aCRTE6E7L2 and TA-CIN Administration for the Treatment of Patients With Persistent HPV16+ ASC-US or LSIL

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Start Date10 Jul 2023

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT04915495

/ Enrolling by invitationNot Applicable

The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia

This study is designed to demonstrate that a multimodal hyperspectral device (LuViva) is able to segregate women with abnormal screening tests into Low and High risk groups for the purpose of determining whether they require enhanced colposcopy and additional biopsies in order to increase detection of CIN2+ cervical disease.

Start Date05 May 2023

Sponsor / Collaborator

Guided Therapeutics, Inc.

100 Clinical Results associated with Atypical Squamous Cells of the Cervix

100 Translational Medicine associated with Atypical Squamous Cells of the Cervix

0 Patents (Medical) associated with Atypical Squamous Cells of the Cervix

1,293

Literatures (Medical) associated with Atypical Squamous Cells of the Cervix

31 Dec 2025·Annals of Medicine

Risk-based triage strategy by extended HPV genotyping for women with ASC-US cytology

Article

Author: Wang, Xin-Yu ; Zhang, Xiao-Fei ; Chen, Rui-Zhe ; Wang, Yue-Han ; Rao, Xuan ; Li, Xiao ; Wu, Qian-Qian ; Fu, Yun-Feng

OBJECTIVEWe attempted to evaluate the immediate high-grade squamous intraepithelial lesion-cervical intraepithelial neoplasia grade 2/3 or worse (HSIL-CIN2+/3+, hereafter referred to as CIN2+/3+) risk of specific human papillomavirus (HPV) genotype and form the precise risk-based triage strategy for atypical squamous cells of undetermined significance (ASC-US) women.METHODSThe clinical data of ASC-US women who underwent HPV genotyping testing and colposcopy were retrospectively reviewed. The distribution and CIN2+/3+ risks of specific HPV genotype were assessed by three approaches. The risk-based triage strategy was further established, and its efficacy in detecting CIN2+/3+ was estimated.RESULTSTotally, 5553 ASC-US women including 3648 HPV-positive and 1905 HPV-negative were analysed. CIN2+/3+ were 662/319 cases, including 639/306 HPV-positive and 23/13 HPV-negative women. HPV16, HPV52, HPV58 and HPV18 were always among the top 5 ranking genotypes, no matter in HPV-positive women or in HPV-positive CIN2+/3+ cases. HPV16 and HPV33 carried the highest risk, while HPV73 and 26 carried the least risk for CIN2+/3+. Based on the immediate CIN2+/3+ risk of specific HPV genotype, 18 HPVs were divided into three risk-stratified groups. Only women infected with HPVs included in group A were necessary for immediate colposcopy. Compared with conventional strategy, this new risk-based strategy not only had higher specificity (CIN2+: p = .00; CIN3+: p = .01) and positive predictive value (CIN2+: p = .00; CIN3+: p = .03) for detecting CIN2+/3+, but also needed fewer colposcopies to identify each CIN2+/3+.CONCLUSIONSA new triage strategy for ASC-US women was successfully constructed based on CIN2+/3+ risks of 14 high-risk and 4 intermediate-risk HPVs, which could significantly reduce unnecessary colposcopies.

01 Jun 2025·JAAD International

Atypical squamous proliferation diagnosed on biopsy has a high risk of representing squamous cell carcinoma

Article

Author: Reed, Katelyn A ; Guo, Ruifeng ; Rozenova, Krasimira A

15 Apr 2025·Cancer Research and Treatment

Application of Machine Learning Algorithms for Risk Stratification and Efficacy Evaluation in Cervical Cancer Screening among the ASCUS/LSIL Population: Evidence from the Korean HPV Cohort Study

Article

Author: Oh, Shin Ah ; Choi, Youn Jin ; Seong, Jaehyun ; Hur, Soo Young ; Lee, Hong Yeon ; Song, Heekyoung

Purpose We assessed human papillomavirus (HPV) genotype-based risk stratification and the efficacy of cytology testing for cervical cancer screening in patients with atypical squamous cells of undetermined significance (ASCUS)/low-grade squamous intraepithelial lesion (LSIL).Materials and Methods Between 2010 and 2021, we monitored 1,273 HPV-positive women with ASCUS/LSIL every 6 months for up to 60 months. HPV infections were categorized as persistent (HPV positivity consistently observed post-enrollment), negative (HPV negativity consistently observed post-enrollment), or non-persistent (neither consistently positive nor negative). HPV genotypes were grouped into high-risk (Hr) groups 1 (types 16, 18, 31, 33, 45, 52, and 58) and 2 (types 35, 39, 51, 56, 59, 66, and 68) and a low-risk group. Hr1 was subdivided into types (a) 16 and 18; (b) 31, 33, and 45; and (c) 52 and 58. Cox regression and machine learning (ML) algorithms were used to analyze progression rates.Results Among 1,273 participants, 17.6% with persistent HPV infections experienced disease progression versus no progression in the HPV-negative group (p < 0.001). Cox analysis revealed the highest hazard ratios (HRs) for Hr1-a (11.6, p < 0.001), followed by Hr1-b (9.26, p < 0.001) and Hr1-c (7.21, p < 0.001). HRs peaked at 12-24 months, with Hr1-a maintaining significance at 24-36 months (10.7, p=0.034). ML analysis identified the final cytology change pattern as the most significant factor, with 14-15 months the optimal time for detecting progression from the first examination.Conclusion In ASCUS/LSIL cases, follow-up strategies should be based on HPV risk types. Annual follow-up was the most effective monitoring for detecting progression/regression.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Atypical Squamous Cells of the Cervix

Basic Info

Related

Analysis